Post-analytical phase

  • Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NHH, Hsiung RG-Y, Hyman B, Iqbal K, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Käser SA, on behalf of the Alzheimer’s Association QC Program Work Group. CSF biomarker variability in the Alzheimer’s Association quality control program. Alzheimer’s & Dementia 2013; 9: 251-261.

  •  

    Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin J-J, Engelborghs S. Comparison of two analytical platforms for the clinical qualification of Alzheimer’s disease biomarkers in pathologically-confirmed dementia. J Alzheimer’s Dis 2012; 33: 117 – 131.

  • Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka S-K, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado, Lewczuk P, Li Q-X, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O’Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HPM, Rissman RA, Scarpini E, Stefanin A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers Alzheimer’s & Dementia 2011;7: 386–395.
  • De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E,  Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ and for the Alzheimer’s Disease Neuroimaging Initiative. Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Arch Neurol 2010;67: 949-956.
  • Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of analytical platforms for cerebrospinal fluid measures of ß-Amyloid 1-42, total tau, and P-tau181 for identifying Alzheimer Disease amyloid plaque pathology. Arch Neurol. 2011; 68: 1137 – 1144.
  • Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter Study. Neurobiol Aging. 2007; 29: 812-818.
  • Schoonenboom NSM, Mulder C, Vanderstichele H, Pijnenburg YAL, Van Kamp GJ, Scheltens P, Mehta PD, Blankenstein MA. Differences and similarities between two frequently used assays for amyloid ß 42 in cerebrospinal fluid. Clin Chem 2005; 51:1-3.
  • Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H,  McCulloch C, Möller H-J, Davies P, Blennow K. Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease: A Comparative Cerebrospinal Fluid Study. Arch Gen Psychiatry. 2004. 61:95-102.   
  • Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM-Y, Shaw LM; and the Alzheimer’s Disease Neuroimaging Initiative. Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimer’s & Dementia 2010;6: 230 – 238.
  • Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009; 65:403-413. 

 

Analytical standardization ⇑